<DOC>
	<DOCNO>NCT03068247</DOCNO>
	<brief_summary>The primary study intent examine biological mechanism associate acute chronic treatment response major depressive disorder ( MDD ) . It hypothesize treatment responsiveness , represent endogenous opioid system function , associate acute improvement mood state 10-week treatment trial MDD . Potential ( bio ) marker treatment effect test psychophysical response placebo active treatment .</brief_summary>
	<brief_title>Neurobiology Treatment Responses MDD</brief_title>
	<detailed_description>Volunteers randomize receive placebo pill commercially available SNRI 10 week . Volunteers undergo image structural functional MRI PET [ 11C ] carfentanil determine baseline μOR BPND change BPND measure acute i.v . medication administration time scan 10-week treatment period . To elicit activation µ-opioid-mediated neurotransmission scanner , utilize introduction medication ( active inactive ) 1mL intravenous port every 4 minute , 15 sec per infusion , start 45 minute radiotracer administration , scan completion . Participants make aware study drug administer time computer-generated human voice record read second-by-second count infusion timing ( 15 sec ) .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Meet DSM V criterion Major Depressive Episode , single episode recurrent , least month ; Unmedicated least 10 halflives previous AD use ; Willing limit introduction new treatment study ; 18 55 year age ; Right hand ; Capable give write informed consent ; Hamilton Depression Rating Scale ( 17item HDRS , include atypical feature ) &gt; 15 screening randomization ; Major medical illness ( e.g. , cancer , HIV , Hepatitis C , etc . ) concurrent , untreated , symptomatic medical illness , include acute ongoing pain , autoimmune inflammatory disease ; Use narcotic analgesic within last 6 month regular use sleeping aid ( include benzodiazepine related compound ) , twice week ; Recent history substance abuse ( within last 6 month ) history substance dependence ( lifetime ) ; Other comorbid psychiatric illness , Bipolar Disorder , Obsessive Compulsive Disorder , Panic Disorder , psychosis , Axis II diagnose . Generalized Anxiety Social Anxiety Disorders NOT consider exclusionary give common association MDD Concurrent participation therapeutic trial ; Pregnancy/nursing ; Ongoing treatment medication psychotropic property ; Contraindications PET MRI method ; Impairments , activity situation would prevent completion study protocol ; Prior nonresponse duloxetine ; Active suicidal ideation . Urine screen positive opioids substance abuse . Allergy fentanyl ( structural similarity radiotracer [ 11C ] carfentanil employ study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>